As part of the deal, which is worth at least $3 million for the first five years, Primerdesign will develop and supply 384-well plate molecular assay panels for Genesis.
The probes are for use in Cancer Genetics' FISH-based HPV-Associated Cancer Test, which measures genomic changes to help triage cervical cancer patients.
Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.
Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.
OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.
Sema4, spun out of Mount Sinai earlier this year, will standardize its two major labs on the Core Informatics Platform for Science as it looks to grow.
OraSure noted that the devices allow ambient temperature transportation and storage of a liquid sample to enable high throughput automation in a laboratory.
British genomics interpretation software vendor Congenica inked a deal with a Portuguese hospital to analyze whole-exome sequencing data for the In2Genome project.
The companies will combine OpGen's Acuitas Rapid Test for Pathogen ID and Thermo Fisher's new mid-throughput real-time PCR system.
WeGene will use DNA Genotek's saliva DNA collection kits for its genetic testing and personalized healthcare services.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.